BioSpace News Archive

Mitutoyo America Corporation is pleased to announce the release of the CRYSTA-Apex V Series to its Coordinate Measuring Machine product line.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the Food and Drug Administration (FDA) granted a third Fast-Track designation to its lead drug candidate, repotrectinib. The designation was granted for the treatment of patients with advanced solid tumors that have an NTRK gene fusion who have progressed following treatment with

Heska Corporation (NASDAQ: HSKA; “Heska” or “Company”), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Stephen Davis , the Chairman and Founder of the Will Group, to the Company’s Board of Directors (the “Board”), effective August 20, 2020 .

Rafael Holdings, Inc., (NYSE: RFL), today announced that it will present at The LD 500 Virtual Conference on Thursday, September 3, 2020 . David Polinsky , Rafael’s Chief Financial Officer, will dis

Ligand Announces Amgen’s KYPROLIS ® Approved by FDA as Combination Regimen with DARZALEX ® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma KYPROLIS is an Amgen product that utilizes Captisol ® in its formulation Approval based on the CANDOR and EQUULEUS Studies SAN DIEGO--( BUSINESS WIRE )-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Capti

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announces today completion of its $2.35 million seed round financing from multiple venture capitalists including Terra Magnum Capital Partners. The Company will use the proceeds to advance its Covid-19

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the first subjects have been dosed with CB4211 in the Phase 1b stage of its Phase 1a/1b clinical trial for NASH and obesity

American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that on July 22, 2020, it had filed with the US Patent and Trademark Office (“USPTO”) a new patent for the treatment of Major Depressive Disorder

Meridian is pleased to announce the appointment of James Kiamos as the President and Chief Executive Officer for Centene’s Illinois market including Meridian in Illinois and YouthCare program effective beginning August 24, 2020.

Today, ATAI Life Sciences (“ATAI” or the “Company”), a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of EmpathBio, a wholly-owned subsidiary developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications.